Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multi-center, double-blind, placebo-controlled study designed to
evaluate the efficacy of crenolanib administered following salvage chemotherapy,
consolidation chemotherapy, post bone marrow transplantation and as maintenance in
relapsed/refractory AML subjects with FLT3 activating mutation.